###begin article-title 0
###xml 89 96 89 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2B </italic>
###xml 99 103 <span type="species:ncbi:9615">dogs</span>
Disruption of chromosome 11 in canine fibrosarcomas highlights an unusual variability of CDKN2B in dogs
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 3 7 <span type="species:ncbi:9615">dogs</span>
###xml 157 162 <span type="species:ncbi:9606">human</span>
###xml 272 275 <span type="species:ncbi:9615">dog</span>
###xml 780 784 <span type="species:ncbi:9615">dogs</span>
In dogs in the western world neoplasia constitutes the most frequently diagnosed cause of death. Although there appear to be similarities between canine and human cancers, rather little is known about the cytogenetic and molecular alterations in canine tumours. Different dog breeds are susceptible to different types of cancer, but the genetic basis of the great majority of these predispositions has yet to be discovered. In some retriever breeds there is a high incidence of soft tissue sarcomas and we have previously reported alterations of chromosomes 11 and 30 in two poorly differentiated fibrosarcomas. Here we extend our observations and present a case report on detail rearrangements on chromosome 11 as well as genetic variations in a tumour suppressor gene in normal dogs.
###end p 3
###begin title 4
Results
###end title 4
###begin p 5
###xml 254 260 254 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2B</italic>
###xml 261 268 261 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A </italic>
###xml 417 423 414 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A</italic>
###xml 462 465 459 462 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ARF</sup>
###xml 471 478 468 475 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2B </italic>
###xml 576 579 <span type="species:ncbi:9615">dog</span>
###xml 804 808 <span type="species:ncbi:9615">dogs</span>
BAC hybridisations on metaphases of two fibrosarcomas showed complex rearrangements on chromosome 11, and loss of parts of this chromosome. Microsatellite markers on a paired tumour and blood DNA pointed to loss of heterozygosity on chromosome 11 in the CDKN2B-CDKN2A tumour suppressor gene cluster region. PCR and sequencing revealed the homozygous loss of coding sequences for these genes, except for exon 1beta of CDKN2A, which codes for the N-terminus of p14ARF. For CDKN2B exon 1, two alleles were observed in DNA from blood; one of them identical to the sequence in the dog reference genome and containing 4 copies of a 12 bp repeat found only in the canine gene amongst all species so far sequenced; the other allele was shorter due to a missing copy of the repeat. Sequencing of this exon in 141 dogs from 18 different breeds revealed a polymorphic region involving a GGC triplet repeat and a GGGGACGGCGGC repeat. Seven alleles were recorded and sixteen of the eighteen breeds showed heterozygosity.
###end p 5
###begin title 6
Conclusion
###end title 6
###begin p 7
###xml 268 275 268 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2B </italic>
Complex chromosome rearrangements were observed on chromosome 11 in two Labrador retriever fibrosarcomas. The chromosome alterations were reflected in the loss of sequences corresponding to two tumour suppressor genes involved in cell-cycle progression. Sequencing of CDKN2B across many different breeds revealed a widespread polymorphism within the first exon of the gene, immediately before the ankyrin coding sequences.
###end p 7
###begin title 8
Background
###end title 8
###begin p 9
###xml 93 115 93 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Canis lupus familiaris</italic>
###xml 660 661 660 661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 662 663 662 663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 834 835 834 835 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 88 91 <span type="species:ncbi:9615">dog</span>
###xml 93 115 <span type="species:ncbi:9615">Canis lupus familiaris</span>
###xml 190 193 <span type="species:ncbi:9615">dog</span>
###xml 241 246 <span type="species:ncbi:9606">human</span>
###xml 380 386 <span type="species:ncbi:9606">humans</span>
###xml 475 480 <span type="species:ncbi:9606">human</span>
###xml 490 494 <span type="species:ncbi:9615">Dogs</span>
###xml 578 581 <span type="species:ncbi:9615">dog</span>
###xml 718 724 <span type="species:ncbi:9606">humans</span>
###xml 729 733 <span type="species:ncbi:9615">dogs</span>
###xml 795 799 <span type="species:ncbi:9615">dogs</span>
###xml 820 825 <span type="species:ncbi:9606">human</span>
Neoplasia is profoundly important as a cause of morbidity and mortality in the domestic dog, Canis lupus familiaris. In addition to its importance as a working animal and a pet species, the dog is an important intermediate model species for human tumour biology. It has a relatively large body size, often displays responses to cytotoxic or other therapeutic agents comparable to humans, and has a relatively high natural incidence of several cancers with similar biology to human tumours. Dogs have been used as models for cancer therapy, such as in osteosarcoma, in the giant dog breeds, oral melanoma and non-Hodgkins lymphoma, amongst others (reviewed in [1,2]. In general, the same tumour types are recognised in humans and dogs; for instance, the classification of soft tissue sarcomas of dogs largely follows the human system [3]. Studies of cytogenetic and genetic changes in canine soft tissue sarcomas may reveal more about their aetiology.
###end p 9
###begin p 10
###xml 103 104 103 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 1035 1041 1035 1041 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TGFBR1</italic>
###xml 1186 1192 1186 1192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TGFBR1</italic>
###xml 1394 1401 1394 1401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TGFBR1 </italic>
###xml 852 855 <span type="species:ncbi:31658">CFA</span>
In a previous study, primary cell cultures were obtained from two poorly differentiated fibrosarcomas [4]. Both tumours (which were name-coded LE and ME) came from adult female Labrador retrievers. Chromosome painting revealed they both had abnormalities in chromosomes 11 (CFA11) and 30 (CFA30). One tumour (LE) contained four translocation chromosomes involving CFA4, CFA11, CFA27 and CFA30 (tumour karyotype 2n = 78; t(4;11;30), t(11;27); t(27;11); t(30;4); der 11 (del 11q)); the second one (ME) had a deletion of CFA11q and trisomy of CFA30 (tumour karyotype 2n = 79; der11; +30). An attempt to isolate the translocation chromosomes by Fluorescence Activated Chromosome Sorting had not allowed complete purification of these chromosomes but PCR of sequence tagged sites (STS), on sorted preparations, had shown that sequences in the first 7 Mb of CFA 27 and the last 20 Mb of CFA11 were present in the LE tumour genome, but missing when t(27;11) was excluded. Rearrangement in the Transforming Growth Factor Beta Receptor 1 gene (TGFBR1) was implied as only a portion of the exonic sequences could be obtained by PCR of DNA in this preparation. In addition to this altered copy of TGFBR1, the tumour still had at least one normal coding sequence of the gene. This tumour sequence was identical to that obtained from blood DNA of the same individual. At least one normal coding sequence of TGFBR1 was also present in the tumour ME. Here we extend our search for molecular alterations of CFA11 that could be linked to canine sarcomas and present a case report involving the loss of heterozygosity in a region harbouring two tumour suppressor genes.
###end p 10
###begin title 11
Results
###end title 11
###begin title 12
Further characterisation of derivative chromosomes by BAC hybridisation
###end title 12
###begin p 13
###xml 288 289 288 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 484 485 484 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
To obtain a more detailed description of rearrangements in chromosome 11 in these fibrosarcomas, eleven canine BACs spaced at intervals along chromosome 11 were used to probe tumour metaphases, in some cases in combination with chromosome paints identifying translocation partners (Table 1). For LE, the distribution of BAC hybridisation suggests that the der11 and t(4;11;30) chromosomes originate from one chromosome 11 whilst t(11;27) and t(27;11) originate from the other (Figure 1). However, the pattern of rearrangements in derivative chromosomes is complex. The der11 chromosome contains both centromeric and telomeric sequences in an inverted arrangement, whilst central parts of this chromosome 11 are found in t(4;11;30) (BACs between 375-F21 and 381-N7 locate here). t(11;27) contains the centromere proximal region of CFA11. Although no BACs more telomeric than 375-F21 hybridised to this chromosome, chromosome painting suggests that more than half of the normal CFA11 is present, so there may be some further interstitial insertion of sequences not represented by the BACs used here. More telomeric BACs hybridised to t(27;11) but, again, these showed rearrangement such that 381-H22 has a sub-telomeric position whilst BACs which lie distal to this in the normal chromosome are now placed near the centre of the derivative. The translocation break/fusion point is close to RP81_381-N7 with BACs derived from centromere proximal sequence found distal to this position in the fusion chromosome.
###end p 13
###begin p 14
BACs used for in situ hybridisation.
###end p 14
###begin p 15
*NA = Data not available.
###end p 15
###begin p 16
###xml 0 69 0 69 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Chromosome painting of metaphases spreads from canine fibrosarcoma LE</bold>
###xml 285 288 <span type="species:ncbi:31658">CFA</span>
Chromosome painting of metaphases spreads from canine fibrosarcoma LE. Chromosome painting of tumour LE (6 colour paints, colours as shown) shows 4 derivative chromosomes containing CFA11 DNA. To look at the distribution of CFA11 BACs, metaphases were hybridised with a mixed paint of CFA 4, 27 and 30 (green) and a single BAC paint as indicated in examples shown, (red). For N7, where the t(27;11) is difficult to identify because of a high green background, additional hybridising chromosomes from other metaphases are shown; inset at twice the scale. Diagrams summarise hybridisation of all BACs with each derivative containing chromosome 11. The red arrowheads denote BACs consistently binding to the chromosomes shown. Chromosomes in the diagram are CFA11 in blue (mid blue -centromeric; light blue -telomeric); CFA27 green; CFA4 yellow; CFA30 purple.
###end p 16
###begin p 17
###xml 123 124 123 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 397 398 397 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
For ME, BACs telomeric of RP81_381-H22 did not hybridise to the derivative chromosome, but RP81_381-H22 itself did (Figure 2). There was also lack of signal from RP81_376-M15 on the derivative, suggesting interstitial deletion of the derivative chromosome in the area of this BAC. In independent RH mapping studies the BAC 381-F14 is placed on chromosome 11 at position 8810, telomeric to 373M14 [5].
###end p 17
###begin p 18
###xml 0 70 0 70 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Chromosome painting of metaphases spreads derived from fibrosarcoma ME</bold>
Chromosome painting of metaphases spreads derived from fibrosarcoma ME. Chromosome painting of tumour ME (6 colour paints, colours as shown) shows a der11 with +/- 40% of the genomic material of the normal chromosome. An example BAC hybridisation is shown, using RP81_381-N7 (red). Diagrams of the normal and derivative chromosome show hybridisation positions of BACs: red arrowheads - BACs consistently binding to both chromosomes; green arrowheads -those not hybridising to the derivative; blue arrowhead -consistent hybridisation to the normal but inconsistent to the der 11 chromosome.
###end p 18
###begin title 19
Loss of heterozygosity
###end title 19
###begin p 20
###xml 263 264 263 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 466 467 466 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 584 589 584 589 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4B</sup>
###xml 594 600 594 600 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4A </sup>
###xml 607 610 607 610 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ARF</sup>
###xml 685 691 685 691 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2B</italic>
###xml 765 771 765 771 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A</italic>
###xml 787 788 787 788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 832 846 832 846 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2B-CDKN2A </italic>
###xml 545 550 <span type="species:ncbi:9606">human</span>
For LE, genomic DNA from blood and tumour was available, while only tumour DNA could be obtained for sample ME. Loss of heterozygosity on CFA11 was analysed for the LE fibrosarcoma. Forty-five microsatellites distributed across the chromosome were studied (Table 2). Complete loss of heterozygosity (loss of the 262 bp allele) was observed for marker CAMC11.029, and a substantial loss (of the 224 bp allele) for marker CAMC11.026 (22% remaining signal) (see Figure 3). The region between these two markers contains sequences orthologous to the human genes coding for the proteins p15INK4B, p16INK4A and p14ARF. The first one is coded by the cyclin-dependent kinase inhibitor 2B gene (CDKN2B), while the other two are coded by cyclin-dependent kinase inhibitor 2A (CDKN2A) [reviewed in [6]]. A marker (CAMC11.027) within the canine CDKN2B-CDKN2A region was uninformative (homozygous in blood and tumour DNA for sample LE). Most other markers showed no change between tumour and blood, but one further marker, (FH4031, 29.9 Mb proximal from CAMC11.026), showed partial loss of one allele (37% remaining signal). For marker CAMC11.004 (10 Mb from CAMC11.026) a discrepancy was observed in the results corresponding to the blood and the tumour; the former presented a heterozygous genotype, while the tumour had a single allele that was different to either of those observed in the blood.
###end p 20
###begin p 21
CFA11 loss of heterozygosity.
###end p 21
###begin p 22
###xml 126 140 126 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2B-CDKN2A </italic>
###xml 254 260 254 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TGFBR1</italic>
###xml 262 274 262 263 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#167;</sup>
*Microsatellites are listed according to their position in Ensembl's CanFam 2.0 (July 2008). The position of exons within the CDKN2B-CDKN2A gene cluster is provided, along with the position of the gap between contigs 16328 and 16329, and the location of TGFBR1. section signThe numbers in the genotype columns correspond to the PCR product sizes (in base pairs) of the alleles, as determined by the sequencing instrument.
###end p 22
###begin p 23
###xml 40 54 40 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2B-CDKN2A </italic>
###xml 0 59 0 59 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Map of the canine region containing the <italic>CDKN2B-CDKN2A </italic>locus</bold>
###xml 238 244 238 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2 </italic>
Map of the canine region containing the CDKN2B-CDKN2A locus. Top, position of CAMC11.026, CAMC11.029, and of the gap in the genomic sequence assembly. Middle, microsatellites presenting loss of heterozygosity; also, position of predicted CDKN2 related exons (darker grey), other unrelated exons (light grey), and canine ESTs in the database (black). Bottom, exon designations used here.
###end p 23
###begin title 24
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2B </italic>
###xml 11 18 11 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A </italic>
CDKN2B and CDKN2A sequencing from tumour DNA
###end title 24
###begin p 25
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A </italic>
###xml 11 18 11 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2B </italic>
###xml 376 377 376 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 378 379 378 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 414 423 414 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A/B </italic>
###xml 751 758 751 758 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A </italic>
###xml 803 804 799 800 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 816 817 812 813 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 1065 1072 1058 1065 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A </italic>
###xml 55 58 <span type="species:ncbi:9615">dog</span>
###xml 398 403 <span type="species:ncbi:9606">human</span>
###xml 719 722 <span type="species:ncbi:9615">dog</span>
CDKN2A and CDKN2B have not been fully described in the dog. No mRNAs or ESTs that completely define these genes are available, and gene prediction programmes do not fully agree with each other or with those EST that are available. In addition, the area is extremely GC rich and has proved difficult to clone or to sequence, containing a gap in the CamFam 2.0 genome assembly [7,8]. Alignments with human and other CDKN2A/B RNAs appear to be the best guide to gene structure. We used these to design PCR primers. To determine whether the expected remaining copy of these genes had any mutations in tumour LE, the predicted exonic sequences, and their flanking intronic sequences, were investigated. Since the gap in the dog reference sequence is where CDKN2A exon 1alpha is expected to be present (Table 2 and Figure 3), it was not studied. However, a PCR product could be obtained for the predicted exon 1beta; this sequence was identical to that observed in blood DNA from the same individual, and to the sequence in the reference genome. In contrast to this, for CDKN2A no PCR products of exon 2 could be obtained from tumour LE's DNA in spite of repeated attempts, but the sequence was obtained from blood DNA and it contained no difference when compared to the reference genome.
###end p 25
###begin p 26
###xml 78 85 78 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2B </italic>
###xml 178 185 178 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2B </italic>
###xml 899 900 899 900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
When using DNA from tumour as template, no PCR products could be obtained for CDKN2B exons 1 and 2 and their flanking intronic sequences. In LE's DNA from blood, the sequence of CDKN2B exon 2 was the same as in the reference genome. Exon 1 of this same gene could not be PCR-amplified from tumour LE but it was amplified using DNA from blood, and then cloned and sequenced. The results showed that this individual was heterozygous, having one allele with the same sequence as the reference genome (g. [109GGC[5]; 124GGGGACGCCGCC[4]]) as well as a shorter allele (g. [109GGC[5]; 124GGGGACGCCGCC[3]]). At the amino acid level the first allele would have five Gly residues followed by four tandem copies of the sequence GlyAspGlyGly (p. [Gly10[5]; Gly15_Gly18[4]]), while the second allele would consist of five Gly followed by only 3 copies of the tetrapeptide (p. [Gly10[5]; Gly15_Gly18[3]]) (Figure 4).
###end p 26
###begin p 27
###xml 17 24 17 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2B </italic>
###xml 0 51 0 51 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Predicted canine <italic>CDKN2B </italic>exon 1 amino acid sequences</bold>
Predicted canine CDKN2B exon 1 amino acid sequences. Alternate Gly residues in the polymorphic region have a grey background, while the GlyAspGlyGly repeats are enclosed in a frame and alternate repeats also have a grey background. In LE's tumour DNA the exon was missing, but not in peripheral blood where it was heterozygous. Alleles are identified in a simplified way (e.g., [2][3]] corresponds to p. [Gly10[2];Gly15_Gly18[3]]).
###end p 27
###begin title 28
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2B </italic>
###xml 34 37 <span type="species:ncbi:9615">dog</span>
CDKN2B exon 1 polymorphism in the dog
###end title 28
###begin p 29
###xml 335 336 335 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 386 387 386 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 409 410 409 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 428 435 428 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2B </italic>
###xml 1079 1080 1079 1080 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 1098 1105 1098 1105 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2B </italic>
###xml 151 155 <span type="species:ncbi:9615">dogs</span>
###xml 461 464 <span type="species:ncbi:9615">dog</span>
###xml 1031 1035 <span type="species:ncbi:9615">dogs</span>
###xml 1131 1134 <span type="species:ncbi:9615">dog</span>
To investigate whether the shorter allele could be related to the development of the neoplasia, the exon was was amplified using DNA from blood of 141 dogs of 18 different breeds. The size of the PCR products was determined by capillary electrophoresis and products corresponding to the different sizes were sequenced directly (Figure 5). Seven different alleles were found (see Figure 6, and Additional file 1: Distribution of CDKN2B exon 1 alleles in various dog breeds). The most frequent allele was p. [Gly10[5]; Gly15_Gly18[4]], which corresponds to the reference sequence and was found in all breeds studied. Alleles p. [Gly10[5]; Gly15_Gly18[3]] and p. [Gly10[4]; Gly15_Gly18[4]] were also observed. Additionally, 4 alleles were rarer in this sample set; the shortest being p. [Gly10[4]; Gly15_Gly18[2]] in Cardigan Welsh corgis, and the longest p. [Gly10[5]; Gly15_Gly18[5]] in a Rottweiler. Among these blood samples, 24 corresponded to flat-coated retrievers; of these 11 had histiocytic sarcoma and 13 were non-affected dogs aged 10 years or more (See Additional file 1: Distribution of CDKN2B exon 1 alleles in various dog breeds). The distribution of the alleles was not significantly different between these two sets (chi-square test p = 0.55). All breeds except boxer (15 individuals examined) and Shih Tzu (two individuals only) were polymorphic at this position
###end p 29
###begin p 30
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2B </italic>
###xml 0 64 0 64 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>CDKN2B </italic>exon 1 genotype determination in dogs of different breeds</bold>
###xml 40 44 <span type="species:ncbi:9615">dogs</span>
CDKN2B exon 1 genotype determination in dogs of different breeds. Dye-labelled PCR products were separated by capillary electrophoresis. Fragments representing all different sizes were sequenced to confirm the identity of the alleles.
###end p 30
###begin p 31
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2B </italic>
###xml 0 65 0 65 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>CDKN2B </italic>exon 1 alleles observed in canine blood and tumour samples</bold>
CDKN2B exon 1 alleles observed in canine blood and tumour samples. Alternate GGC triplets coding for Gly have a grey background. The dodecameric nucleotide sequence (GGGGACGGCGGC) coding for the GlyAspGlyGly repeats are within a box, with alternate repeats having a grey background. Intronic sequences are in lowercase. Alleles are identified with a short version of their description; e.g., [4][2]] stands for g. [109GGC[4];124GGGGACGGCGGC[2]]. The [5][4]] allele corresponds to the reference genome (CanFam2.0).
###end p 31
###begin title 32
###xml 6 13 6 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2B </italic>
###xml 17 24 17 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A </italic>
###xml 45 48 <span type="species:ncbi:9615">dog</span>
Other CDKN2B and CDKN2A polymorphisms in the dog
###end title 32
###begin p 33
###xml 69 76 69 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2B </italic>
###xml 141 144 <span type="species:ncbi:9615">dog</span>
To search for additional polymorphisms in these two genes, exon 2 of CDKN2B was studied using DNA from blood samples from a Bernese mountain dog, four boxers, nine flat-coated retrievers (four with histiocytic sarcoma and five free from neoplasia), two golden retrievers and a Labrador retriever. No polymorphisms were seen in the coding region or the flanking intronic bases.
###end p 33
###begin p 34
###xml 10 17 10 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A </italic>
###xml 390 396 390 396 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4A </sup>
###xml 403 406 403 406 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ARF</sup>
###xml 537 541 537 541 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ARF </sup>
###xml 549 550 549 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7</xref>
###xml 587 593 587 593 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4A </sup>
###xml 615 616 615 616 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8</xref>
###xml 101 105 <span type="species:ncbi:9615">dogs</span>
Exon 2 of CDKN2A was also sequenced from DNA obtained from blood samples from three Bernese mountain dogs, four flat-coated retrievers with histiocytic sarcoma, and five flat-coated retrievers free from tumours, two golden retrievers and four Labrador retrievers. A coding SNP was identified that led to a non-synonymous change in the predicted codon 19 of exon 2 that is shared by both p16INK4A and p14ARF. The polymorphism was a g.1206A>G transversion that corresponds to a p.Gln79Arg change in the predicted amino acid sequence of p14ARF (Figure 7) and an Asn to Asp change in the p16INK4A reading frame (Figure 8). Both alleles were found in all breeds studied, except in the boxer where all four individuals were homozygous for the reference sequence. In the flat-coated retrievers half of the histiocytic sarcoma cases were GG homozygous and the rest AG heterozygous, while two controls were homozygous GG and three were heterozygous.
###end p 34
###begin p 35
###xml 33 40 33 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A </italic>
###xml 50 54 50 54 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ARF </sup>
###xml 0 106 0 106 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Polymorphism in exon 2 of canine <italic>CDKN2A </italic>in the p14<sup>ARF </sup>reading frame and alignment to orthologous sequences</bold>
###xml 112 115 <span type="species:ncbi:9615">dog</span>
Polymorphism in exon 2 of canine CDKN2A in the p14ARF reading frame and alignment to orthologous sequences. The dog polymorphic residue is highlighted in yellow.
###end p 35
###begin p 36
###xml 33 40 33 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A </italic>
###xml 50 56 50 56 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4A </sup>
###xml 0 108 0 108 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Polymorphism in exon 2 of canine <italic>CDKN2A </italic>in the p16<sup>INK4A </sup>reading frame and alignment to orthologous sequences</bold>
###xml 308 311 <span type="species:ncbi:9615">dog</span>
###xml 352 355 <span type="species:ncbi:9615">dog</span>
Polymorphism in exon 2 of canine CDKN2A in the p16INK4A reading frame and alignment to orthologous sequences. The canine polymorphic position is highlighted in yellow in the loop joining the second and third ankyrin repeats. The alpha helix residues of the ankyrin repeats have a grey background. CanFam2.0 -dog reference genome; BMD -Bernese Mountain dog with the alternative Asp residue; CMT28_FJ542308 -canine mammary tumour cell line; NCF_FJ542309 -cultured canine fibroblasts.
###end p 36
###begin title 37
Discussion
###end title 37
###begin p 38
A previous analysis of two canine fibrosarcomas with rearrangement of chromosome 11 was followed up by BAC mapping. In both tumours this revealed that rearrangements were more complex than had been seen using chromosome painting. In LE all chromosomes containing fragments of chromosome 11, except t(11;27), showed interstitial deletions and or rearrangements. In ME a deletion around BAC M15 was observed. Loss of heterozygosity (LOH) on chromosome 11 was studied in LE's tumour. Marker CAMC011.004 (34.56 Mb) presented an allele in the tumour which was different from any of those in the blood. This result was confirmed in two independent experiments. This marker is within a gene desert, with no proven transcripts encoded or genes modelled within about a megabase. Our data does not show whether this marker is close to a rearrangement. FH4031 (14.24 Mb), which shows LOH, is also some way from the nearest known gene. In this case more proximal markers are not informative. It seems likely that, in the tumour, the der11 and t(4;11;30) chromosomes have lost some sequences in this region, which is near the proximal chromosome breakpoint in both.
###end p 38
###begin p 39
###xml 96 102 96 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2B</italic>
###xml 103 110 103 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A </italic>
###xml 246 253 246 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A </italic>
###xml 257 263 257 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2B</italic>
###xml 352 359 352 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A </italic>
###xml 631 638 628 635 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A </italic>
###xml 663 670 657 664 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2B </italic>
###xml 1006 1013 1000 1007 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TFGBR1 </italic>
###xml 1078 1079 1072 1073 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 1192 1193 1186 1187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1177 1182 <span type="species:ncbi:9606">human</span>
Loss of heterozygosity was also observed in two markers which bracket a region encompassing the CDKN2B-CDKN2A gene cluster. Even though the microsatellite study pointed to loss of heterozygosity rather than complete loss of the region containing CDKN2A and CDKN2B, no PCR products could be obtained from the tumour for the genes themselves, except for CDKN2A exon 1beta. The sequence of this exon showed no differences with the reference one. A microsatellite within the gene cluster could be amplified but it was homozygous in blood and thus non-informative regarding loss of heterozygosity. This microsatellite is 8 kb away from CDKN2A exon 1beta and 3 kb from CDKN2B exon 2, which could not be detected in the tumour DNA. These results suggest that two copies of parts of chromosome 11 are present in the tumour, while other regions are present only once, and still others, close to the latter, are completely missing. This complex pattern is reminiscent of the alterations observed for t(27;11), where TFGBR1 exons 3 to 6 and 9 were observed, but not the rest of the exons [4]. This agrees also with the recent observation on the complexity of chromosome rearrangements in human tumours [9].
###end p 39
###begin p 40
###xml 197 199 197 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 224 231 224 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2B </italic>
###xml 235 241 235 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A</italic>
###xml 278 283 278 283 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4B</sup>
###xml 315 321 315 321 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4A </sup>
###xml 328 332 328 332 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ARF </sup>
###xml 447 449 447 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 450 452 450 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 458 464 458 464 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4A </sup>
###xml 471 475 471 475 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ARF </sup>
###xml 519 522 519 522 <sup xmlns:xlink="http://www.w3.org/1999/xlink">RB1</sup>
###xml 695 701 695 701 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A</italic>
###xml 772 774 772 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 891 893 891 893 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 894 896 894 896 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 899 906 899 906 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A </italic>
###xml 983 985 979 981 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 986 988 982 984 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1024 1028 1020 1024 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Arf </sup>
###xml 1056 1059 1052 1055 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ARF</sup>
###xml 1067 1072 1063 1068 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Ink4b</sup>
###xml 1142 1144 1138 1140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1145 1147 1141 1143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 1244 1246 1240 1242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1426 1428 1422 1424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1477 1482 1473 1478 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4B</sup>
###xml 1487 1493 1483 1489 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4A </sup>
###xml 1499 1503 1495 1499 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ARF </sup>
###xml 1523 1525 1519 1521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 1619 1621 1615 1617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1622 1624 1618 1620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1625 1627 1621 1623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1683 1690 1679 1686 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2B </italic>
###xml 1694 1701 1690 1697 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A </italic>
###xml 1738 1740 1734 1736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 1790 1796 1786 1792 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4A </sup>
###xml 1851 1853 1847 1849 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1895 1897 1891 1893 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1955 1961 1951 1957 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4A </sup>
###xml 2109 2111 2105 2107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 2137 2143 2133 2139 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4A </sup>
###xml 2306 2312 2302 2308 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4A </sup>
###xml 2396 2398 2392 2394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 2442 2448 2438 2444 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4A </sup>
###xml 2534 2536 2530 2532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 2791 2797 2787 2793 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4A </sup>
###xml 2804 2808 2800 2804 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ARF </sup>
###xml 2816 2817 2812 2813 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7</xref>
###xml 2829 2830 2825 2826 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8</xref>
###xml 131 136 <span type="species:ncbi:9606">human</span>
###xml 182 187 <span type="species:ncbi:9606">human</span>
###xml 635 640 <span type="species:ncbi:9606">human</span>
###xml 721 726 <span type="species:ncbi:10090">mouse</span>
###xml 731 736 <span type="species:ncbi:9606">human</span>
###xml 994 998 <span type="species:ncbi:10090">mice</span>
###xml 1047 1052 <span type="species:ncbi:9606">human</span>
###xml 1153 1159 <span type="species:ncbi:9606">humans</span>
###xml 1633 1638 <span type="species:ncbi:9606">human</span>
###xml 1639 1647 <span type="species:ncbi:9606">patients</span>
###xml 1752 1756 <span type="species:ncbi:9615">dogs</span>
###xml 2433 2438 <span type="species:ncbi:9606">human</span>
Both approaches, BAC mapping and loss of heterozygosity, point to alterations on canine chromosome 11, in the region equivalent to human chromosome 9p21 which is commonly deleted in human tumours [10] and contains the genes CDKN2B and CDKN2A. The first codes for the protein p15INK4B, while the second codes for p16INK4A and p14ARF which are proteins derived from alternate exon 1 sequences and use different reading frames for the common exon 2 [11,12]. p16INK4A and p14ARF regulate the retinoblastoma protein 1 (pp105RB1) and the tumour protein 53 (TP53), respectively. These form part of the two pathways most commonly disrupted in human tumours. Recently a new protein, smARF, also coded by CDKN2A, was identified in mouse and human and localised in the mitochondria [13]. It has been shown to inhibit cell growth and proliferation, and to induce apoptosis in a TP53-independent manner [14,15]. CDKN2A also codes for the proteins p12 and p16gamma which are less well understood [16,17]. In mice, disruption of either p19Arf (the orthologue of human p14ARF) or p16Ink4b, or both, results in increased predisposition to tumour development [18-21]. In humans, homozygous deletions are the most frequent type of mutation involving these genes [22], as opposed to the combination of mono-allelic deletion followed by the mutation of the remaining copy of the gene, which is the common pattern in other tumour suppressor genes [23]. However, alterations affecting only one of p15INK4B, p16INK4A or p14ARF have been reported [11]. Apart from homozygous deletions, 5'CpG methylation has also been observed in some tumours [12,24-26]. In human patients with soft tissue sarcomas, loss of CDKN2B and CDKN2A is associated with reduced survival [27], while in dogs, absence or reduced levels of p16INK4A have been reported in melanoma tumours and cell lines [28], as well as in osteosarcoma cell lines [29]. In canine non-Hodgkin's lymphoma (NHL), deletion of p16INK4A or loss of CFA11 have been observed in high-grade T-cell NHL, without comparable alterations seen in high-grade B-cell NHL or in low grade tumours [30]. In this same paper, p16INK4A methylation was observed in a single low-grade T-cell lymphoma. In addition to this, in two canine mammary tumour cell lines, CMT12 and CMT27, no expression of p16INK4A was observed, while in a third cell line (CMT28) increased expression was detected [31]. Upon transfection of a complete human p16INK4A cDNA, these cell lines lost most of the characteristics of the transformed phenotype [31]. The sequences of CMT28 and of canine fibroblast cultured cells were reported to differ from the reference sequence, although the nucleotide and the aminoacid sequences are identical to the canine reference sequences used here for the second exon of p16INK4A and p14ARF (Figure 7 and Figure 8).
###end p 40
###begin p 41
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A </italic>
###xml 57 62 54 59 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ARF. </sup>
###xml 300 302 297 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 303 305 300 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 306 308 303 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 338 345 331 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A </italic>
###xml 369 375 362 368 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4A </sup>
###xml 396 398 389 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 668 673 655 660 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 685 687 672 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 779 783 763 767 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ARF </sup>
###xml 833 839 817 823 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4A </sup>
###xml 882 884 866 868 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 966 968 950 952 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 1011 1018 992 999 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A </italic>
###xml 1099 1103 1080 1084 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ARF </sup>
###xml 1294 1297 1272 1275 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ARF</sup>
###xml 1419 1425 1397 1403 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4A </sup>
###xml 1432 1435 1410 1413 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ARF</sup>
###xml 1527 1532 1505 1510 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4A</sup>
###xml 1581 1583 1559 1561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 1690 1696 1668 1674 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4A </sup>
###xml 1697 1699 1675 1677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 1700 1702 1678 1680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 1959 1961 1937 1939 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 314 321 <span type="species:ncbi:9031">chicken</span>
###xml 1312 1319 <span type="species:ncbi:9031">chicken</span>
###xml 1838 1842 <span type="species:ncbi:9615">dogs</span>
CDKN2A exon 1beta codes for the N-terminus portion of p14ARF. The first amino-acid residues of this protein are relatively well conserved and have an important role in binding MDM2 while the rest of the protein, containing a nucleolar localization signal, is poorly conserved and may be dispensable [11,32,33]. In chicken, exon 1alpha of CDKN2A has been lost and no p16INK4A protein is produced [34]. Exon 1beta is spliced to the still existent exon 2 but the predicted protein terminates at the end of exon 1beta, with no residues from exon 2. In spite of this, the protein is able to bind MDM2 thus preventing the induction of TP53 degradation and the inhibition of TP53 expression [34]. It is therefore likely that exon 1beta codes for the amino acid residues required for p14ARF to perform its normal role. Moreover, aberrant p16INK4A transcripts have been observed in tumours [35] and some of them are translated and are able to function in cell-cycle control [36]. In the present study only exon 1beta of CDKN2A was observed in LE's fibrosarcoma. It is possible that an abnormal version of p14ARF could have been produced; it is unknown whether the remaining exon 1beta would have been spliced to another sequence, generating an abnormal transcript and, possibly, a shorter version of p14ARF, as is in the chicken. In the current study, a polymorphism was observed in exon 2 causing missense mutations in both p16INK4A and p14ARF. The polymorphic residue is in the loop joining the second and thitd ankyrin repeats of p16INK4A. This residue is on the surface of the protein [37]. Although it does not interact with CDK6, it does seem to have a role in stabilising the structure of p16INK4A [38,39]. In other species this position is occupied by the acidic residues Asp or Glu, so the polar neutral Asn residue seems to be unique to dogs. However, other structurally related proteins with ankyrin repeats have Asn in the equivalent position (e.g., p18) [37].
###end p 41
###begin p 42
###xml 87 89 87 89 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 90 92 90 92 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 246 253 246 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2B </italic>
###xml 256 260 <span type="species:ncbi:9615">dogs</span>
Polymorphisms in short repeat sequences within coding exons have been observed before [40,41], whilst somatic repeat instabilities are well documented in other species both in tumours and in some degenerative diseases. The putative first exon of CDKN2B in dogs has a predicted GlyAspGlyGly repeat that is not found in other species. This exon is represented in the database by two ESTs [GenBank:  and GenBank: ]. The multiplicity of alleles in this gene may have resulted from occasional misalignments during crossover events between homologous chromosomes, leading to the expansion and contraction in the number of GGC triplet and GGGGACGGCGGC dodecamer repeats. No instances were observed of nonsense mutations in this region, nor were indels found that would produce shifts in the reading frame. In the case of flat-coated retrievers, which show a high predisposition to developing histiocytic sarcomas, cases and controls were found to have a similar distribution of exon 1 alleles. Moreover, the sequences obtained from genetic material from blood samples of various breeds suggest that the variation in the number of Gly residues and in the number of GlyAspGlyGly repeats is a normal polymorphism in this species.
###end p 42
###begin p 43
###xml 3 8 3 8 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4B</sup>
###xml 19 25 19 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2B</italic>
###xml 110 115 110 115 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4A</sup>
###xml 120 126 120 126 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4C </sup>
###xml 133 138 133 138 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4D</sup>
###xml 313 315 313 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 321 327 321 327 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4B </sup>
###xml 334 340 334 340 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4A </sup>
###xml 419 421 419 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 528 530 528 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 545 551 545 551 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4A </sup>
###xml 716 718 716 718 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 719 721 719 721 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 722 724 722 724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 784 790 784 790 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4B </sup>
p15INK4B, coded by CDKN2B, and the rest of the members of the inhibitor of kinase 4 (INK4) protein family (p16INK4A, p18INK4C and p19INK4D) have ankyrin repeats that play an important role in the folding of the protein and in intermolecular interactions with other proteins, such as the cyclin-dependent kinases [39]. p15INK4B and p16INK4A are similar proteins that appear to be the result of a gene duplication event [42]; both have 4 ankyrin repeats and they appear to function in a similar manner and may be interchangeable [43]. However, p16INK4A has been studied in more detail. It is known, for example, that this protein's loops 1 and 2, as well as some of the ankyrin repeats themselves, interact with CDK6 [38,44-46]. The GlyAspGlyGly repeats predicted to exist in canine p15INK4B are immediately before helix alpha1 of the first ankyrin repeat. Hence the polymorphism may not disrupt the folding or function of the protein which is dependent on the ankyrin repeats and the loops connecting them. These GlyAspGlyGly repeats would introduce a region of small glycine residues punctuated by charged aspartates causing a difference in molecular size at the N-terminus of the protein.
###end p 43
###begin p 44
###xml 3 9 3 9 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4B </sup>
###xml 67 69 67 69 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 70 72 70 72 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 171 178 171 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2B </italic>
###xml 179 181 179 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 284 291 284 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TGFBR1 </italic>
###xml 292 293 292 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 478 484 478 484 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4B </sup>
###xml 491 497 491 497 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4A </sup>
###xml 612 616 612 616 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ARF </sup>
p15INK4B is induced by transforming growth factor, beta 1 (TGFB1) [47-49]; this induction may be direct, through the binding of TGFB1 to a sequence within the promoter of CDKN2B [50]. In a previous study we showed that the breakpoint of the translocation chromosome t(27;11) involves TGFBR1 [4] which codes for a receptor to TFGB1. However, the tumour still contained a complete coding sequence of the gene. It seems, therefore, that the pathway is disrupted at the level of p15INK4B and p16INK4A through the homozygous deletion of their coding sequences, while the possibility still remains that an abnormal p14ARF could be present.
###end p 44
###begin title 45
Conclusion
###end title 45
###begin p 46
###xml 142 148 142 148 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4B </sup>
###xml 166 173 166 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2B </italic>
###xml 418 425 418 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2B </italic>
###xml 250 253 <span type="species:ncbi:9615">dog</span>
###xml 510 513 <span type="species:ncbi:9615">dog</span>
In fibrosarcomas studied in this work complex rearrangements of canine chromosome 11 were observed, causing changes in genes in the TGFB - p14INK4B pathway. Study of CDKN2B showed unusual variants present in exon 1 of the gene in different breeds of dog, as a result of a simple repeat sequence. No instances of missense or frameshifting mutations were observed. However, it is possible that the genomic plasticity of CDKN2B observed here is connected with the rather high frequency of cancers in the domestic dog.
###end p 46
###begin title 47
Methods
###end title 47
###begin title 48
Tumours and blood samples
###end title 48
###begin p 49
###xml 97 98 97 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 38 42 <span type="species:ncbi:9615">dogs</span>
###xml 291 295 <span type="species:ncbi:9615">dogs</span>
The two tumours, corresponding to two dogs name-coded LE and ME, have been described previously [4]. Both are fibrosarcomas from adult Labrador retriever females from the pet population. Blood samples were obtained from excess material used for the purpose of clinical diagnostic studies of dogs admitted to the Queens Veterinary School Hospital of the University of Cambridge.
###end p 49
###begin title 50
Fluorescence-in-situ Hybridisation
###end title 50
###begin p 51
###xml 153 155 153 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 205 207 205 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
Chromosome paints for seven colour FISH and other combinations of single colour canine chromosome paints were prepared and used as described previously [51]. BACs were from the RPCI-81 canine BAC library [52], and DNA's from them were labeled with biotin-dUTP or digoxigenin-dUTP by nick translation. For hybridization, 300 ng of labeled DNA in 1 mul TE representing one chromosome paint probe mix, or 50 ng of labeled BAC DNA, was mixed with 14 mul hybridization buffer (55% formamide,11% dextran sulphate, 2.2 x SSC, 45 mM sodium phosphate pH7,1.1x Denhardt's solution (Sigma), 0.5 mM EDTA, 45 mug/ml canine Cot-1 DNA), heated at 70C for 10 minutes, then left 20-30 minutes at 37degreesC to allow pre-annealing of the Cot-1 DNA. Metaphase preparations on glass slides were denatured, dried and hybridized to the denatured probes. Hybridization was overnight at 37degreesC in a humid chamber. Slides were washed two x 5 mins in 50% formamide/50% 2 x SSC at 45C followed by two x 5 mins in 2 x SSC at 45degreesC and a final wash in 4 x SSC, 0.01% Tween20 before application of fluorochrome-conjugated antibodies.
###end p 51
###begin p 52
###xml 509 511 497 499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 218 224 <span type="species:ncbi:9986">rabbit</span>
###xml 260 264 <span type="species:ncbi:9925">goat</span>
###xml 270 276 <span type="species:ncbi:9986">rabbit</span>
Biotin labeled probes were visualized using Cy3-avidin (single colour FISH) or Cy5-avidin (multi-colour FISH) (1:500 dilution, Amersham). FITC labeled probes were visualized using sequential application and washing of rabbit anti-FITC (1:200) and FITC-labeled goat anti-rabbit antibodies (1:100). After 20 minutes incubation at 37degreesC, excess antibody was washed off by three 5 minute washes in 4 x T at 42degreesC. Slides were mounted with Vectashield containing DAPI and images were captured as before [53]. Fluorescence signals were captured separately as 8-bit black and white images through appropriate excitation filters, normalized, and merged into a 24-bit colour image. 10 - 15 metaphases were captured for each probe mix.
###end p 52
###begin title 53
DNA extraction form blood
###end title 53
###begin p 54
###xml 235 242 235 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2B </italic>
###xml 15 23 <span type="species:ncbi:9606">patients</span>
###xml 25 27 <span type="species:ncbi:9606">LE</span>
For one of the patients (LE) blood was available and DNA was extracted using the QIAamp DNA Blood Mini kit (QIAGEN) according to the manufacturer's instructions. This same extraction procedure was used for the bloods used to study the CDKN2B exon 1 polymorphism in 18 breeds.
###end p 54
###begin title 55
Loss of heterozygosity analysis
###end title 55
###begin p 56
###xml 286 287 286 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 415 421 415 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2B</italic>
###xml 422 429 422 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A </italic>
###xml 443 450 443 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TFGBR1 </italic>
###xml 615 617 615 617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 672 674 672 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 675 677 675 677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
###xml 926 928 924 926 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 15 17 <span type="species:ncbi:9606">LE</span>
###xml 253 256 <span type="species:ncbi:9615">dog</span>
###xml 508 511 <span type="species:ncbi:9615">dog</span>
For individual LE, for which tumour and blood DNA was available, loss of heterozygosity analysis was performed. Microsatellite markers were chosen along the canine chromosome 11; the location of non CAMC markers and their primer sequences appear in the dog reference genome in Ensembl [7]. To fill the gaps between adjacent markers, and to increase the density in some regions of interest, such as those around the CDKN2B-CDKN2A locus and the TFGBR1 gene, additional microsatellites were identified from the dog reference sequence: appropriate contig sequences were analysed with Tandem Repeat Finder version 4.00 [54] and primers were designed manually or using Primer3 [55,56]. These markers carry the prefix CAMC in the name. All PCR reactions had a final volume of 10 mul, with 1 to 10 ng of genomic DNA as template, 5 U of Taq polymerase (Invitrogen), a final concentration of 0.2 pmol/mul for each primer, 1.5 mM of MgCl2 and 0.25 mM of each dNTP. For markers with the CAMC prefix, the PCR products were labelled indirectly using a two-step amplification procedure. For these markers, the forward marker-specific primer had a T7 universal sequence (5'-TAATACGACTCACTATAGGG-3') added to its 5' end. These markers, with forward and reverse primer sequences (omitting the T7 sequence from the forward primer), are: CAMC11.001 (AAATGGTCCATCAGAG, ACTAGCTAAGAACTTCATGG); CAMC11.002 (AGTGCTTTGATGCTGA, GAAAGACCTACATTAGTACC); CAMC11.003 (ATAAGACCAAACCTAC, TCTCATGTTTCTGAAGAGTG); CAMC11.004 (AAGTAGCCATACTAAT, CTCAGACCTTATCTATTTGG); CAMC11.005 (ATGGGTATTAAAGACG, CCAAACTGAACCAACATGAG); CAMC11.006 (AACACTCAGTCAAGCC, ATCGGACTCCTTCCATGCTG); CAMC11.007 (CTTGGATAAGCTCTGC, TTCTGGACAGTACTACATTC); CAMC11.008 (GGAGGGGGATTGGTTTTGAT, ATGCTCACTCACTCGCATGT); CAMC11.009 (CCTGTTGGAACTGGAGCTTT, TTTGGGATAATCTAAAGCAAATC); CAMC11.010 (GGGTACCTTCTTTCGGCATT, CATAGCTGACTCCCTTGAAG); CAMC11.011 (CCCTCATACCACGGCTTTTA, ATGACCAAAACTGCCCAGAG); CAMC11.012 (TTCTTCTTTGGGAGTTGCACA, TTCAGCTCCCTTGGAAACTC); CAMC11.013 (ATGGTAGATGGAGGACCTGA, CAGGATGTGTGAAGGGGAG); CAMC11.014 (GGCAGAGGGTGGGTAAAATA, GCCGCCCTGTATGCCTTTT); CAMC11.015 (ACATGTGAAGGCAACCATTTG, TTGCTTAGACAGTATGAAATATG); CAMC11.016 (TTATCCCTGGAAACCCAACAT, TGGCCAAGGTTACACAGTAG); CAMC11.017 (GATGGGACAAGTGTCAAAGG, TTGTCCTCTGAGCAAGTCTG); CAMC11.018 (CAGGAGCCCACTCCTTTTTA, GAGTGACTGTGCGTGTGTG); CAMC11.019 (GCACATGAGGACCCTTCAAT, ATGTCATGGAAAACTGCAAGC); CAMC11.020 (AGTAAACACTACCACATCTGG, TCAGGTGGAGCCAGGTTTTA); CAMC11.021 (ATCATGGAACCCAGAGCAAC, AAGCCAGCTCATCAAGGAGA); CAMC11.022 (TCCTGAGAAAGGCCTGGATA, GCCCGTCAAGTTAGTGAGG); CAMC11.023 (CTGCCAACTCCTCCTCTGT, CCCTCCCAACTGTTCCAAAT); CAMC11.024 (AACAGCAGGACAAAGTCTGC, ATATCATTCGTGGCCCTTCC); CAMC11.026 (TCATGGGTCATGAGATGGAC, GCCCTCATGAATGGGATTAG); CAMC11.027 (CACAGAATAACTCAATAGGTTG, ACTTCTGTGAAGTGCCTTATG); CAMC11.029 (GGTTCAAGTTCAGAATGCTTG, GTTTAGCGTTAGCGCCTGC). For the first PCR these unlabelled primers were used; 1 mul of these products were then used as template for a second PCR reaction with a T7 primer having a D2, D3 or D4 label (Proligo) on its end. The first PCR reaction was a touch-down PCR with an initial annealing temperature of 66degreesC; this temperature was decreased by 1degreesC for 12 cycles, followed by 30 cycles with an annealing temperature of 54degreesC. For the second PCR 25 cycles were performed with an annealing temperature of 54degreesC. For all PCRs, each step had a duration of 20 sec. For markers whose name does not have the prefix CAMC, the PCR amplifications were performed with a single reaction using forward primers labelled with D2, D3 or D4 (Proligo). After PCR amplification, regardless of whether one or two step reactions had been performed, all PCR products were diluted 1:8 to 1:12 using sterile water. Two microlitres of each diluted product were mixed with 0.15 mul of D1-labelled GenomeLab DNA size standard 600 (Beckman Coulter) and 30 mul of GenomeLab Sample Loading Solution containing formamide (Beckman Coulter). The products were then run in a CEQ8000 sequencer (Beckman Coulter) and genotypes were retrieved with the instrument's Fragment Analysis software. This same program was used to determine loss of heterozygosity, by comparing the peaks obtained from the blood sample and for the matching tumour. Loss of heterozygosity was noted when either peak showed a greater than 30% loss of signal.
###end p 56
###begin title 57
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2B </italic>
###xml 11 18 11 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A </italic>
CDKN2B and CDKN2A sequencing
###end title 57
###begin p 58
###xml 35 42 35 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2B </italic>
###xml 46 53 46 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A </italic>
###xml 249 256 249 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2B </italic>
###xml 370 377 358 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2B </italic>
###xml 493 500 469 476 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A </italic>
###xml 617 624 581 588 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A </italic>
###xml 733 740 685 692 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2B </italic>
###xml 744 751 696 703 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A </italic>
###xml 1100 1107 1050 1057 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2B </italic>
###xml 1534 1541 1484 1491 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2B </italic>
###xml 2223 2224 2166 2167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 2225 2226 2168 2169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 2264 2271 2207 2214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2B </italic>
###xml 2288 2291 2231 2234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p14</italic>
###xml 2291 2294 2234 2237 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ARF</italic>
###xml 2291 2294 2234 2237 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>ARF</italic></sup>
###xml 2295 2301 2238 2244 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A</italic>
###xml 2404 2406 2347 2349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B57">57</xref>
###xml 2407 2409 2350 2352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B58">58</xref>
Primers were designed for studying CDKN2B and CDKN2A exonic sequences plus the flanking intronic bases. The primer names, sequences (5' to 3'), starting and ending annealing temperatures for touchdown PCR, and PCR product sizes were as follows. For CDKN2B exon 1 primers 1729 (GAAACAGGGAGGCGAGTGAC) and 1730 (CGCAGATACGTCGGCGAAGC), 70degreesC to 58degreesC, 388 bp; for CDKN2B exon 2 primers 1731 (GAAATGGTCCACCTGTCCCTG) and 1732 (CACCGTGACTCAAGTCTCCTG), 72degreesC to 60degreesC, 470 bp; for CDKN2A exon 1b primers 2257 (GAGCTTCCACCCCTAGAAAC) and 2258 (CGGCTCCGAGATCGGAGG), 72degreesC to 60degreesC, 526 bp; and for CDKN2A exon 2 primers 1727 (CTTGTAGCGGCATCTGCATGG) and 1728 (TGCTCTGGGCTGCGGAAG), 72degreesC to 62degreesC, 459 bp. CDKN2B and CDKN2A sequences are GC-rich, so they were PCR-amplified with AccuPrime GC-Rich DNA polymerase (Invitrogen) using Buffer A for that enzyme. PCRs were done in 40 mul, using 6 to 30 ng of genomic DNA, a final concentration of 02.pmol/mul for each primer and 1.6 U of the polymerase. All amplifications were done using touchdown-PCR. PCR products, except for CDKN2B exon 1, were cleaned with the QIAquick PCR purification kit (QIAGEN), sequenced with the GenomeLab DTCS kit (Beckman Coulter) and ran in a CEQ8000 sequencer. Sequences were analysed and aligned against the canine genomic reference sequences using the Sequence Analysis and Sequence Investigator modules on the sequencer. Differences with respect to the reference sequence were confirmed by sequencing the complementary strand. CDKN2B exon 1 PCR fragments from tumour samples were cloned and then sequenced. AccuPrime's GC-rich polymerase proofreading activity yields blunt-ended products; to clone the fragments into the PCR4-TOPO vector of the TOPO TA Cloning Kit for Sequencing (Invitrogen) a 3' A-overhang was incorporated to the PCR products by incubating them with 1 mul of Taq polymerase (Invitrogen) at 72degreesC for 10 min. Sequencing reactions with the GenomeLab DTCS kit were performed according to the manufacturer's protocol for plasmid templates except that betaine (Sigma) was added to a final concentration of 1 M. The reference sequences used were CanFam 2.0, assembly May 2006, Genebuild Sep 2008 [7,8] for the canine genome; [EMBL: ] for CDKN2B and [EMBL: ] for p14ARF/CDKN2A. Polymorphisms and mutations in these sequences are described following the recommended nomenclature [57,58].
###end p 58
###begin title 59
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2B </italic>
CDKN2B exon 1 polymorphism search
###end title 59
###begin p 60
###xml 17 24 17 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2B </italic>
###xml 338 339 338 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1546 1548 1503 1505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B59">59</xref>
###xml 1575 1577 1532 1534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B60">60</xref>
###xml 1601 1603 1558 1560 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B61">61</xref>
###xml 1664 1670 1621 1627 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4B </sup>
###xml 1721 1740 1678 1697 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xenopus tropicalis </italic>
###xml 1751 1769 1708 1726 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Rattus norvegicus </italic>
###xml 1780 1793 1737 1750 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mus musculus </italic>
###xml 1804 1815 1761 1772 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bos taurus </italic>
###xml 1826 1841 1783 1798 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Macaca mulatta </italic>
###xml 1852 1868 1809 1825 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pan troglodytes </italic>
###xml 1879 1892 1836 1849 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Homo sapiens </italic>
###xml 1925 1931 1882 1888 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4A </sup>
###xml 1937 1955 1894 1912 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Takifugu rubripes </italic>
###xml 1966 1988 1923 1945 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Monodelphis domestica </italic>
###xml 1999 2010 1956 1967 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bos taurus </italic>
###xml 2021 2036 1978 1993 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Equus caballus </italic>
###xml 2047 2058 2004 2015 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sus scrofa </italic>
###xml 2069 2081 2026 2038 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mus spretus </italic>
###xml 2092 2110 2049 2067 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Rattus norvegicus </italic>
###xml 2121 2134 2078 2091 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mus musculus </italic>
###xml 2153 2165 2110 2122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Felis catus </italic>
###xml 2176 2192 2133 2149 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pan troglodytes </italic>
###xml 2203 2216 2160 2173 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Homo sapiens </italic>
###xml 2270 2274 2227 2231 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ARF </sup>
###xml 2275 2296 2232 2253 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mesocricetus auratus </italic>
###xml 2307 2325 2264 2282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Rattus norvegicus </italic>
###xml 2336 2342 2293 2299 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mus sp</italic>
###xml 2355 2368 2312 2325 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Homo sapiens </italic>
###xml 66 69 <span type="species:ncbi:9615">dog</span>
###xml 1721 1739 <span type="species:ncbi:8364">Xenopus tropicalis</span>
###xml 1751 1768 <span type="species:ncbi:10116">Rattus norvegicus</span>
###xml 1780 1792 <span type="species:ncbi:10090">Mus musculus</span>
###xml 1804 1814 <span type="species:ncbi:9913">Bos taurus</span>
###xml 1826 1840 <span type="species:ncbi:9544">Macaca mulatta</span>
###xml 1852 1867 <span type="species:ncbi:9598">Pan troglodytes</span>
###xml 1879 1891 <span type="species:ncbi:9606">Homo sapiens</span>
###xml 1937 1954 <span type="species:ncbi:31033">Takifugu rubripes</span>
###xml 1966 1987 <span type="species:ncbi:13616">Monodelphis domestica</span>
###xml 1999 2009 <span type="species:ncbi:9913">Bos taurus</span>
###xml 2021 2035 <span type="species:ncbi:9796">Equus caballus</span>
###xml 2047 2057 <span type="species:ncbi:9823">Sus scrofa</span>
###xml 2069 2080 <span type="species:ncbi:10096">Mus spretus</span>
###xml 2092 2109 <span type="species:ncbi:10116">Rattus norvegicus</span>
###xml 2121 2133 <span type="species:ncbi:10090">Mus musculus</span>
###xml 2153 2164 <span type="species:ncbi:9685">Felis catus</span>
###xml 2176 2191 <span type="species:ncbi:9598">Pan troglodytes</span>
###xml 2203 2215 <span type="species:ncbi:9606">Homo sapiens</span>
###xml 2275 2295 <span type="species:ncbi:10036">Mesocricetus auratus</span>
###xml 2307 2324 <span type="species:ncbi:10116">Rattus norvegicus</span>
###xml 2355 2367 <span type="species:ncbi:9606">Homo sapiens</span>
To determine the CDKN2B exon 1 alleles present in a collection of dog DNAs of different breeds, the exon was amplified, along with the flanking intronic sequences, using a D4 (Sigma) labelled forward primer 1729 and an unlabelled reverse primer 1730. The length of the product, according to the reference sequence in CanFam2.0 is 388 bp [7]. PCRs were performed using the KAPA2G Robust PCR Kit (Kapabiosystems, Cape Town, South Africa), with buffer B and Kapa Enhancer 1, in a volume of 10 mul, with a minimum of 8 ng of template and a touchdown-PCR starting with an annealing temperature of 72degreesC, and decreasing by 1degreesC per cycle to 59degreesC, followed by 25 cycles with an annealing temperature of 58degreesC. Annealing, extension (at 72degreesC) and denaturation (at 95degreesC) were 20 sec long each. The products were diluted 1:8 with sterile water and loaded on a CEQ8000 sequencer (Beckman Coulter) to determine the size of the PCR products with the Fragment Analysis module of the instrument; 18.25% of the samples were retested to confirm the results. 22.63% of the samples, representing the different allele sizes observed, were amplified again from genomic DNA and sequenced directly with the GenomeLab DTCS kit following the procedure recommended by the manufacturer for GC-rich sequences. Cleaned products were separated on the CEQ8000 at 60degreesC and results analysed as in the sequences described in the previous section. Multiple alignments of nucleotide and predicted amino acid sequences were done with ClustalW2 [59] at the EMBL-EBI website [60] or using JalView 2.3 [61] and then manually edited. GenBank accession numbers for p15INK4B amino acid sequences used for the alignments were [Xenopus tropicalis GenBank: , Rattus norvegicus GenBank: , Mus musculus GenBank: , Bos taurus GenBank: , Macaca mulatta GenBank: , Pan troglodytes GenBank: , Homo sapiens GenBank: ]. The sequences for p16INK4A were [Takifugu rubripes GenBank: , Monodelphis domestica GenBank: , Bos taurus GenBank: , Equus caballus GenBank: , Sus scrofa GenBank: , Mus spretus GenBank: , Rattus norvegicus GenBank: , Mus musculus UniProt: P51480-1, Felis catus GenBank: , Pan troglodytes GenBank: , Homo sapiens GenBank: , CMT28 GenBank: , NCF GenBank: ] and for p14ARF [Mesocricetus auratus GenBank: , Rattus norvegicus GenBank: , Mus sp. GenBank: , Homo sapiens GenBank: ].
###end p 60
###begin p 61
###xml 261 263 261 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B62">62</xref>
In the flat-coated retrievers allele distribution between cases and controls was compared using a Monte Carlo simulation of the chi-square test and grouping together columns with expected values lower than 5, as implemented in the T2 test of the program Clump [62]; the level of significance was determined by performing 10000 simulations.
###end p 61
###begin title 62
Competing interests
###end title 62
###begin p 63
The authors declare that they have no competing interests.
###end p 63
###begin title 64
Authors' contributions
###end title 64
###begin p 65
JAH performed the LOH study, the sequencing of tumour samples, the DNA extraction and sequencing of blood samples, the alignments and bioinformatics analyses and wrote the manuscript. BM established the primary cell cultures, carried out the cytogenetic studies and made the chromosome paints. CQ performed the BAC mapping. PCMO flow-sorted the chromosomes. TH collected the biological samples and maintained the information database associated with it. SH performed the pathological diagnosis of the tumours and other biopsy samples. MAFS participated in the design of the study and in the interpretation of the results. JMD participated in the design of the project and in the collection of samples. DRS conceived and directed the project, interpreted the cytogenetic and BAC mapping results, analysed the sequencing data and participated in writing the manuscript. All authors read and approved the final manuscript.
###end p 65
###begin title 66
Supplementary Material
###end title 66
###begin title 67
Additional file 1
###end title 67
###begin p 68
###xml 16 23 16 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2B </italic>
###xml 0 59 0 59 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Distribution of <italic>CDKN2B </italic>exon 1 alleles in various dog breeds</bold>
###xml 49 52 <span type="species:ncbi:9615">dog</span>
Distribution of CDKN2B exon 1 alleles in various dog breeds. Cells show number of individuals for the corresponding genotypes and alleles. In the heading, genotypes and alleles are described in a simplified way (e.g., allele g. [109GGC[2];124GGGGACGGCGGC[3] appears as [2][3], while the heterozygous combination of g. [109GGC[2];124GGGGACGGCGGC[3] and g. [109GGC[5];124GGGGACGGCGGC[3] is shown as [2][3][5][3]. In the flat-coated retrievers, HS denotes histiocytic sarcoma).
###end p 68
###begin p 69
Click here for file
###end p 69
###begin title 70
Acknowledgements
###end title 70
###begin p 71
These studies were supported by the Pet Plan ChariTable Trust and Cancer Research UK grant reference C8876/A4012. BM received a Domestic Research Studentship from Cambridge University. Some of the DNA samples used in this study were kindly provided by Keiko Miyadera, Veterinary Medicine, University of Cambridge. This project benefited from the use of the University of Cambridge's federated computational grid (CamGrid).
###end p 71
###begin article-title 72
###xml 37 40 <span type="species:ncbi:9615">Dog</span>
###xml 48 51 <span type="species:ncbi:9606">man</span>
Comparative aspects of osteosarcoma. Dog versus man
###end article-title 72
###begin article-title 73
###xml 66 71 <span type="species:ncbi:9606">human</span>
Spontaneously occurring tumors of companion animals as models for human cancer
###end article-title 73
###begin article-title 74
Chromosome rearrangements in canine fibrosarcomas
###end article-title 74
###begin article-title 75
A 1-Mb resolution radiation hybrid map of the canine genome
###end article-title 75
###begin article-title 76
Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all
###end article-title 76
###begin article-title 77
Ensembl
###end article-title 77
###begin article-title 78
###xml 78 81 <span type="species:ncbi:9615">dog</span>
Genome sequence, comparative analysis and haplotype structure of the domestic dog
###end article-title 78
###begin article-title 79
###xml 50 55 <span type="species:ncbi:9606">human</span>
Architectures of somatic genomic rearrangement in human cancer amplicons at sequence-level resolution
###end article-title 79
###begin article-title 80
###xml 70 75 <span type="species:ncbi:9606">human</span>
Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers
###end article-title 80
###begin article-title 81
INK4a/ARF: a multifunctional tumor suppressor locus
###end article-title 81
###begin article-title 82
The p16INK4a/CDKN2A tumor suppressor and its relatives
###end article-title 82
###begin article-title 83
A short mitochondrial form of p19ARF induces autophagy and caspase-independent cell death
###end article-title 83
###begin article-title 84
The autophagic inducer smARF interacts with and is stabilized by the mitochondrial p32 protein
###end article-title 84
###begin article-title 85
###xml 119 124 <span type="species:ncbi:10090">mouse</span>
Small mitochondrial ARF (smARF) is located in both the nucleus and cytoplasm, induces cell death, and activates p53 in mouse fibroblasts
###end article-title 85
###begin article-title 86
###xml 44 49 <span type="species:ncbi:9606">human</span>
Tissue-specific alternative splicing in the human INK4a/ARF cell cycle regulatory locus
###end article-title 86
###begin article-title 87
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human p16gamma, a novel transcriptional variant of p16(INK4A), coexpresses with p16(INK4A) in cancer cells and inhibits cell-cycle progression
###end article-title 87
###begin article-title 88
###xml 66 70 <span type="species:ncbi:10090">mice</span>
Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice
###end article-title 88
###begin article-title 89
###xml 54 58 <span type="species:ncbi:10090">mice</span>
Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis
###end article-title 89
###begin article-title 90
###xml 25 30 <span type="species:ncbi:10090">mouse</span>
Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF
###end article-title 90
###begin article-title 91
The differential impact of p16(INK4a) or p19(ARF) deficiency on cell growth and tumorigenesis
###end article-title 91
###begin article-title 92
###xml 48 53 <span type="species:ncbi:9606">human</span>
CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines
###end article-title 92
###begin article-title 93
RB1 gene mutations in retinoblastoma
###end article-title 93
###begin article-title 94
###xml 106 111 <span type="species:ncbi:9606">human</span>
Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells
###end article-title 94
###begin article-title 95
###xml 114 119 <span type="species:ncbi:9606">human</span>
5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers
###end article-title 95
###begin article-title 96
p16(MTS-1/CDKN2/INK4a) in cancer progression
###end article-title 96
###begin article-title 97
Alterations of INK4A and INK4B genes in adult soft tissue sarcomas: effect on survival
###end article-title 97
###begin article-title 98
Expression and significance of p53, rb, p21/waf-1, p16/ink-4a, and PTEN tumor suppressors in canine melanoma
###end article-title 98
###begin article-title 99
Inactivation of p53 and retinoblastoma family pathways in canine osteosarcoma cell lines
###end article-title 99
###begin article-title 100
Inactivation of the p16 cyclin-dependent kinase inhibitor in high-grade canine non-Hodgkin's T-cell lymphoma
###end article-title 100
###begin article-title 101
Phenotype-rescue of cyclin-dependent kinase inhibitor p16/INK4A defects in a spontaneous canine cell model of breast cancer
###end article-title 101
###begin article-title 102
ARF function does not require p53 stabilization or Mdm2 relocalization
###end article-title 102
###begin article-title 103
Stabilization of p53 by p14ARF without relocation of MDM2 to the nucleolus
###end article-title 103
###begin article-title 104
###xml 63 71 <span type="species:ncbi:9031">chickens</span>
Absence of p16INK4a and truncation of ARF tumor suppressors in chickens
###end article-title 104
###begin article-title 105
###xml 68 73 <span type="species:ncbi:9606">human</span>
Frequent detection of aberrant RNA transcripts of the CDKN2 gene in human gastric adenocarcinoma
###end article-title 105
###begin article-title 106
Aberrant p16INK4A RNA transcripts expressed in hepatocellular carcinoma cell lines regulate pRb phosphorylation by binding with CDK4, resulting in delayed cell cycle progression
###end article-title 106
###begin article-title 107
###xml 13 18 <span type="species:ncbi:9606">human</span>
Structure of human cyclin-dependent kinase inhibitor p19INK4d: comparison to known ankyrin-repeat-containing structures and implications for the dysfunction of tumor suppressor p16INK4a
###end article-title 107
###begin article-title 108
Tumor suppressor INK4: determination of the solution structure of p18INK4C and demonstration of the functional significance of loops in p18INK4C and p16INK4A
###end article-title 108
###begin article-title 109
Ankyrin repeat: a unique motif mediating protein-protein interactions
###end article-title 109
###begin article-title 110
Expanded repeat in canine epilepsy
###end article-title 110
###begin article-title 111
Molecular origins of rapid and continuous morphological evolution
###end article-title 111
###begin article-title 112
###xml 55 60 <span type="species:ncbi:9606">human</span>
One INK4 gene and no ARF at the Fugu equivalent of the human INK4A/ARF/INK4B tumour suppressor locus
###end article-title 112
###begin article-title 113
p15Ink4b is a critical tumour suppressor in the absence of p16Ink4a
###end article-title 113
###begin article-title 114
Tumor suppressor p16INK4A: determination of solution structure and analyses of its interaction with cyclin-dependent kinase 4
###end article-title 114
###begin article-title 115
Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a
###end article-title 115
###begin article-title 116
Tumor suppressor INK4: quantitative structure-function analyses of p18INK4C as an inhibitor of cyclin-dependent kinase 4
###end article-title 116
###begin article-title 117
p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest
###end article-title 117
###begin article-title 118
###xml 139 144 <span type="species:ncbi:9606">human</span>
Transforming growth factor beta stabilizes p15INK4B protein, increases p15INK4B-cdk4 complexes, and inhibits cyclin D1-cdk4 association in human mammary epithelial cells
###end article-title 118
###begin article-title 119
Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta
###end article-title 119
###begin article-title 120
Transforming growth factor beta activates the promoter of cyclin-dependent kinase inhibitor p15INK4B through an Sp1 consensus site
###end article-title 120
###begin article-title 121
Karyotype of canine soft tissue sarcomas: a multi-colour, multi-species approach to canine chromosome painting
###end article-title 121
###begin article-title 122
###xml 60 63 <span type="species:ncbi:9615">dog</span>
Construction and characterization of an eightfold redundant dog genomic bacterial artificial chromosome library
###end article-title 122
###begin article-title 123
###xml 46 49 <span type="species:ncbi:9615">dog</span>
###xml 51 58 <span type="species:ncbi:9627">red fox</span>
###xml 64 69 <span type="species:ncbi:9606">human</span>
A complete comparative chromosome map for the dog, red fox, and human and its integration with canine genetic maps
###end article-title 123
###begin article-title 124
Tandem repeats finder: a program to analyze DNA sequences
###end article-title 124
###begin article-title 125
Primer3 on the WWW for general users and for biologist programmers
###end article-title 125
###begin article-title 126
Primer3 (v. 0.4.0)
###end article-title 126
###begin article-title 127
HGVS, nomenclature for the description of sequence variations
###end article-title 127
###begin article-title 128
Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion
###end article-title 128
###begin article-title 129
Clustal W and Clustal X version 2.0
###end article-title 129
###begin article-title 130
EMBL-EBI, ClustalW2
###end article-title 130
###begin article-title 131
The Jalview Java alignment editor
###end article-title 131
###begin article-title 132
Monte Carlo tests for associations between disease and alleles at highly polymorphic loci
###end article-title 132

